Ipamorelin: Complete Research Guide — Selective GH Secretagogue Mechanism, Human Data & White-Label Pricing (2026)

What Is Ipamorelin (NNC-26-0161) and Where Does It Come From?

Ipamorelin (CAS: 170851-70-4, also designated NNC-26-0161) is a synthetic pentapeptide growth hormone secretagogue developed by researchers at Novo Nordisk A/S in Denmark. Updated April 2026. First described in a landmark 1998 publication in the European Journal of Endocrinology, ipamorelin was identified within a series of compounds derived from growth hormone-releasing peptide (GHRP)-1 by removing the central Ala-Trp dipeptide — a modification that preserved GH-releasing potency while dramatically improving receptor selectivity (Raun et al., Eur J Endocrinol, 1998 — PMID: 9849822).

The Raun et al. paper described ipamorelin as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH” — a characterization that remains accurate in the literature today. What sets ipamorelin apart from earlier GH secretagogues (GHRP-2, GHRP-6, hexarelin) is its remarkable hormonal specificity: published data shows it does not significantly elevate ACTH, cortisol, prolactin, FSH, LH, or TSH even at doses more than 200-fold above the GH-releasing ED50.

Key Characteristics

How Does Ipamorelin Work? Primary Mechanisms of Action

Ipamorelin produces GH release through selective agonism of a single receptor — GHS-R1a — without engaging the broader neuroendocrine signaling networks activated by earlier-generation GH secretagogues. Understanding this selectivity is the key to interpreting both the research utility and the comparative profile of ipamorelin versus other compounds in the GH axis category.

GHS-R1a Agonism and Pulsatile GH Release

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the G-protein-coupled receptor whose endogenous ligand is ghrelin. Binding at this receptor activates phospholipase C via Gαq/11 signaling, leading to IP3-mediated calcium release from the somatotroph endoplasmic reticulum and subsequent GH exocytosis from anterior pituitary cells (Raun et al., Eur J Endocrinol, 1998 — PMID: 9849822).

Critically, ipamorelin produces a pulsatile GH release pattern — a discrete, time-limited spike rather than sustained elevation. Published pharmacokinetic-pharmacodynamic modeling in human volunteers documented a GH peak at approximately 40 minutes post-administration, with return to baseline within 3 hours (Gobburu et al., Pharm Res, 1999 — PMID: 10496658). This pulsatile profile mirrors endogenous GH secretion patterns, which is mechanistically relevant for avoiding the receptor desensitization associated with continuous GH stimulation.

Selectivity: Why Ipamorelin Does Not Elevate Cortisol or Prolactin

The defining pharmacological feature of ipamorelin is its hormonal selectivity. In the original Novo Nordisk characterization studies in swine, administration of GHRP-2 and GHRP-6 produced significant elevations in ACTH and cortisol. Ipamorelin, by contrast, did not elevate ACTH or cortisol at doses more than 200-fold above the GH-releasing ED50. FSH, LH, PRL, and TSH were also unaffected. The molecular basis for this selectivity is the presence of the non-standard Aib and D-2-Nal residues, which confer high GHS-R1a binding affinity while minimizing engagement with ACTH-releasing pathways (Raun et al., Eur J Endocrinol, 1998 — PMID: 9849822).

Complementary Signaling with GHRH-Pathway Peptides

Ipamorelin and GHRH-pathway peptides (sermorelin, CJC-1295) act via distinct but synergistic mechanisms. Ipamorelin activates GHS-R1a; GHRH-class compounds activate the GHRH receptor (GHRHR). Published research demonstrates that co-administration of GHS-R1a agonists with GHRH receptor agonists produces supra-additive GH release compared to either compound alone — the scientific basis for the CJC-1295 + ipamorelin combination research model and the commercially formulated 2X Blend.

What Tissue and System Types Has Ipamorelin Been Investigated For?

Ipamorelin’s research literature spans GH-axis pharmacology, bone biology, gastrointestinal motility, and visceral pain research — all downstream of its primary GHS-R1a mechanism.

Longitudinal Bone Growth Research

One of the earliest published applications of ipamorelin in preclinical models was bone growth stimulation. Johansen et al. (1999) used ipamorelin subcutaneously three times daily for 15 days to adult female rats at doses of 18, 90, and 450 μg/day. Longitudinal bone growth rate, measured by intravital tetracycline labeling of the proximal tibia metaphysis, was significantly increased in a dose-dependent manner. Body weight and GH pulse amplitude also increased, consistent with a sustained pituitary GH-releasing effect (Johansen et al., Growth Horm IGF Res, 1999 — PMID: 10373343).

Bone Formation Under Glucocorticoid Challenge

Andersen et al. (2001) studied ipamorelin in a rat model of glucocorticoid-induced bone loss — a clinically relevant model for osteoporosis and steroid-induced skeletal deterioration. Published data demonstrated that ipamorelin administration counteracted the glucocorticoid-induced reduction in bone formation, with histomorphometric analysis showing preservation of osteoblast activity compared to glucocorticoid-only controls. The study supported ipamorelin’s potential utility in skeletal integrity research models (Andersen et al., Growth Horm IGF Res, 2001 — PMID: 11735244).

Gastrointestinal Motility Research

GHS-R1a receptors are expressed throughout the gastrointestinal tract, and ipamorelin has been studied as a ghrelin mimetic for GI motility applications. Greenwood-Van Meerveld et al. (2012) demonstrated that ipamorelin accelerated gastric emptying in a rodent model of postoperative ileus through stimulation of gastric contractility via cholinergic excitatory neurons downstream of GHS-R1a activation (Greenwood-Van Meerveld et al., J Exp Pharmacol, 2012 — PMID: 27186127).

Visceral and Somatic Nociception Research

More recent published research has investigated ghrelin mimetics including ipamorelin in visceral and somatic pain models. Mohammadi et al. (2020) demonstrated attenuation of visceral and somatic nociception by ghrelin mimetics in rodent models, expanding the published research applications of GHS-R1a agonists beyond GH-axis biology into pain research contexts (Mohammadi et al., J Exp Pharmacol, 2020 — PMID: 32801950).

What Does the Human Research Data Show So Far?

Human data for ipamorelin exists in two categories: a pharmacokinetic/pharmacodynamic study in healthy volunteers and a Phase 2 randomized controlled trial in surgical research subjects. This is a more substantial human evidence base than most research peptides in the GH axis category.

Human Safety Summary

The Beck et al. Phase 2 trial is notable for two reasons: it provides the most rigorous published human safety data for ipamorelin as a standalone compound, and it demonstrates tolerability at a clinically relevant dosing schedule. The primary efficacy endpoint for postoperative ileus was not met, though ipamorelin was well tolerated. All ipamorelin products from YPB are classified as Research Use Only (RUO) and are not intended for human potential wellness benefit.

How Does Ipamorelin Compare to Other GH-Axis Research Peptides?

The GH-axis research peptide category includes compounds acting on two distinct receptor systems: GHS-R1a agonists (ipamorelin, GHRP-2, GHRP-6, hexarelin) and GHRH-receptor agonists (sermorelin, CJC-1295). Ipamorelin’s published profile positions it uniquely within the GHS-R1a class.

Ipamorelin is frequently paired with CJC-1295 No DAC in research protocols because their mechanisms are complementary and non-overlapping: GHS-R1a + GHRHR co-activation produces supra-additive GH release. The 2X Blend (Research Use Only) formalizes this combination in a single research SKU. For GHRH-pathway context, the Sermorelin Research Guide covers the oldest-studied GHRH-pathway compound in depth.

What Should Researchers Know About Ipamorelin Stability and Handling?

Ipamorelin at 711.85 Da is a small peptide by research standards — significantly smaller than TB-500 (4,963 Da) or CJC-1295 — which confers both stability advantages and specific reconstitution considerations.

Storage and Reconstitution Protocol

Lyophilized ipamorelin is stable at −20°C for up to 24 months when protected from moisture and light. Reconstitution with bacteriostatic water is recommended over sterile water for preparations intended for extended use, as bacteriostatic water inhibits microbial growth. Once reconstituted, the solution should be held at 2–8°C and used within 14 days. The pentapeptide structure with non-standard Aib and D-2-Nal residues confers resistance to enzymatic degradation compared to natural L-amino acid peptides of similar size, contributing to its approximately 2-hour half-life in preclinical models.

COA Verification

For a 711.85 Da peptide, HPLC purity (≥98%) combined with mass spectrometry confirmation is the appropriate verification standard. At this molecular weight, MS verification is straightforward and reliably distinguishes full-length ipamorelin from synthetic byproducts. Researchers should additionally confirm the presence of the amide C-terminus (Lys-NH2) rather than the carboxylic acid form, as this structural feature is essential for GHS-R1a binding activity. All YPB ipamorelin batches include lot-traceable documentation accessible through the COA Library.

Key Research Findings: Ipamorelin in 2026

Why Is Ipamorelin a High-Demand Research Compound?

Ipamorelin generates 49,500 monthly US searches — the second-highest search volume in the GH secretagogue category after Sermorelin (40,500/mo) — with a demand profile driven by its clean selectivity profile, the large CJC-1295 co-search cluster, and growing consumer-side awareness through the longevity and biohacking research communities.

Search Volume and Consumer Interest

Ipamorelin and CJC-1295 are co-searched more than any other peptide pairing in the GH-axis category. A significant portion of ipamorelin search queries explicitly reference the combination — “ipamorelin CJC-1295,” “ipamorelin CJC-1295 research” — which means white-label brands offering the 2X Blend can capture both compound-specific and combination search traffic simultaneously. The Tesamorelin Research Guide covers a closely adjacent GHRH-pathway compound that also contributes to the GH-axis search cluster.

Publication Velocity

PubMed indexes 150+ publications for ipamorelin and NNC-26-0161 combined. The 2020 visceral nociception publication and a 2025 preprint (Preprints.org) referencing ipamorelin in musculoskeletal peptide research reflect continued active investigation across multiple organ systems. The original 1998 Raun et al. paper has been cited over 400 times, indicating sustained scientific interest in ipamorelin as a reference compound for GHS-R1a biology.

Market Demand Indicators

How Can Researchers Offer Ipamorelin Under Their Own Brand?

YourPeptideBrand.com provides a white-label dropship model for research peptide operators: researcher’s brand name, their pricing, YPB’s lab-tested inventory and fulfillment. Ipamorelin is available as a standalone 10mg compound and as part of the 2X Blend — the most-searched GH-axis combination in the YPB catalog.

What White-Labeling Means

White-label operators receive a fully built WooCommerce storefront with product pages that include pre-built RUO disclaimers, molecular data tables, and COA library links. Operators set retail pricing and keep the full margin. YPB handles fulfillment on every order. Download the product catalog for the full 60+ SKU list and pricing tiers.

Ipamorelin Wholesale Pricing & Margin Analysis

Use the YPB Profit Calculator to model projected monthly revenue at your target pricing and volume. Ipamorelin 10mg at Premier tier generates $93.32 gross margin per unit at $120 MSRP — the highest percentage margin (78%) of any standalone compound in the GH-axis category. 250+ white-label brands are already live on the platform.

Who This Is For

Ipamorelin’s 49,500 monthly searches, low keyword difficulty, and natural CJC-1295 pairing make it one of the most accessible entry points into the GH-axis category for new white-label research brands. Operators offering ipamorelin alongside CJC-1295 No DAC capture both individual-compound search traffic and the high-volume combination co-search cluster, maximizing catalog coverage from two SKUs.

Methodology & Data Sources

References

Frequently Asked Questions

Key Takeaways

Research Takeaways

• Ipamorelin is the first selective GH secretagogue — the original GHS-R1a agonist documented to release GH without co-elevating cortisol, ACTH, prolactin, or appetite signals, even at doses >200× above the GH-releasing ED50.
• Pulsatile GH profile mirrors endogenous secretion patterns — published PK/PD modeling documents GH peak at ~40 minutes with baseline return within 3 hours, avoiding receptor desensitization associated with continuous stimulation.
• Bone growth and bone preservation data are published — longitudinal bone growth stimulation (Johansen et al., 1999) and glucocorticoid-induced bone loss counteraction (Andersen et al., 2001) are documented in peer-reviewed preclinical studies.
• GI motility data extends the research profile beyond the GH axis — GHS-R1a expression in the GI tract enables ipamorelin research in gastric motility and postoperative ileus contexts.
• Phase 2 human RCT completed (2014) — 87-research subjects multicenter trial confirms tolerability at 0.03 mg/kg BID; primary POI endpoint not met, but safety profile established.
• Synergistic with GHRH-pathway peptides — GHS-R1a + GHRHR co-activation produces supra-additive GH release, the mechanistic basis for the CJC-1295 + ipamorelin combination research model.
• Nociception research published 2020 — ghrelin mimetics including ipamorelin demonstrated visceral and somatic pain attenuation in rodent models, expanding the research application landscape.

Business Takeaways

• 49,500 monthly searches at low KD — second-highest search volume in the GH-axis category with a large CJC-1295 co-search cluster that drives combined compound traffic.
• $93.32 gross margin per unit at Premier tier — 78% margin rate, the highest of any standalone GH-axis compound in the YPB catalog at $120 MSRP.
• 2X Blend multiplies SKU value — offering ipamorelin, CJC-1295, and the 2X Blend together captures three product pages from a single compound pairing with minimal content duplication.
• Phase 2 human data supports credibility — the Beck et al. (2014) publication gives white-label brand operators a peer-reviewed human trial reference, differentiating ipamorelin from compounds with only preclinical data.

Ready to add ipamorelin to your research peptide catalog? Schedule a strategy call with the YPB team to discuss storefronts, pricing tiers, and the full GH-axis product line.

[ypb_studies peptide=”ipamorelin”]